## AMERICAN LUNG ASSOCIATION

**National Board** of Directors January 4, 2016

Dear Representative: Chair

John F. Emanuel, JD

Vice-Chairs Penny J. Siewert Karin A. Tollefson, PharmD

The American Lung Association urges you to oppose H.R. 21, the so-called Midnight Rules Relief Act of 2017. Under this bill, Congress could permanently block multiple critical public health protections with a single vote.

Secretary/Treasurer Stephen R. O'Kane

**Past Chair** Kathryn A. Forbes, CPA H.R. 21 is based on a misguided perception that rules finalized toward the end of a presidential administration have not been fully formed or vetted. The reality is that these rules, many of which protect public health, are often the product of years of work and public input.

## **Directors**

Linn P. Billingsley, BSN Larry Blumenthal Michael F. Busk, MD, MPH Cheryl A. Calhoun, BA, MBA **Christopher Carney** Michael V. Carstens Mario Castro, MD, MPH Kathleen Skambis, JD Sumita B. Khatri, MD, MS Robert K. Merchant, MD, MS Stephen J. Nolan, Esq. Harry Perlstadt, Ph.D, MPH Jane Z. Reardon, MSN Al Rowe Jeffrey T. Stein, CFP H.R. 21 would expand the Congressional Review Act to allow *en bloc* disapproval of all regulations finalized near the end of a president's term. The CRA is an extreme tool – it allows Congress to, with a vote of disapproval, not only erase a regulation, but also prevent the federal government from issuing any rule that is "substantially the same" in the future. Allowing an en bloc vote to permanently block a group of regulations is reckless and extreme.

If it became law, H.R. 21 could be used to block lifesaving public health protections that prevent death and disease caused by air pollution and tobacco.

We urge you to oppose this attack on lifesaving public health protections.

Sincerely,

Hardel Wimmer

**National President and CEO** Harold P. Wimmer

Leticia W. Towns

Hanley Wheeler

Harold P. Wimmer **National President and CEO** American Lung Association

**Advocacy Office:** 

1331 Pennsylvania Avenue NW, Suite 1425 North Washington, DC 20004-1710 Ph: 202-785-3355 F: 202-452-1805

Corporate Office: